Click on the links below to preview selected pages from this course.
- Cardiac and Vascular Disease
- Organizations and Agencies
- The Human Heart
- Which heart chamber pumps oxygenated blood out to the body?
- Terminology Describing Ischemic Heart Disease and Heart Failure
- Acute Coronary Syndrome
- Risk Factors for Heart Disease
- Ischemia refers to necrotic tissue caused by an infarcted blood supply.
- Congestive heart failure (CHF) ordinarily results when the left ventricular myocardium is weakened.
- Fibrous Cap
- Monitoring Lipids
- A buildup of plaque that occurs with atherosclerosis may eventually lead to which of the following events?
- Biomarkers of Cardiac Disease
- Biomarkers of An AMI
- Biomarkers in CHF
- Cardiac Biomarkers and Congestive Heart Failure (CHF)
- Function of BNP
- BNP Versus NT-ProBNP
- BNP Versus NT-proBNP, continued
- BNP and NT-ProBNP Measurement and Ranges
- What is the function of the hormone, BNP?
- A 79-year-old diabetic and retired homemaker lives alone since the death of her husband 5 years ago. At age 75, she was diagnosed with an AMI and had ...
- Risk Stratification and Cardiac Biomarkers
- Biomarkers to Identify Those at Risk for Developing Cardiac Disease
Level of instruction: Intermediate
Intended Audience: Clinical laboratory technologists and technicians, and other health care personnel who have an interest in this subject matter. This course is also appropriate for medical laboratory science students and pathology residents.
Author information: Mary Ellen Koenn, MS, MLS(ASCP) is an associate professor emeritus, West Virginia University School of Medicine, Medical Laboratory Science Program. During her career as a medical technologist and educator, she has been a laboratory supervisor and manager and has held several teaching positions. She is the author of numerous articles for laboratory publications and textbook chapters and is a frequent presenter at laboratory seminars and workshops. Ms. Koenn holds a Master of Science degree in Medical Technology.
Reviewer information: Kevin F. Foley, PhD, DABCC, MT, SC is the Northwest chemistry, toxicology, immunology and POC director for Kaiser Permanente. He also teaches pharmacology, clinical chemistry, immunology and medicinal chemistry at Oregon Health Sciences University. Dr. Foley earned his PhD in clinical pharmacology and toxicology at East Carolina School of Medicine in North Carolina. His research areas include cardiovascular risk and inflammation markers as well as the neuropharmacology of amphetamine-like compounds. He is a frequent contributor to several clinical laboratory publications and is active in the American Association of Clinical Chemistry.